Literature DB >> 25158273

Comparison of long-term efficacy of desmopressin lyophilisate and enuretic alarm for monosymptomatic enuresis and assessment of predictive factors for success: a randomized prospective trial.

Fikret Fatih Önol1, Rasim Guzel2, Ahmet Tahra2, Cevdet Kaya2, Ugur Boylu2.   

Abstract

PURPOSE: We compared the long-term success of desmopressin sublingual lyophilisate formulation and enuretic alarm therapy in children with primary monosymptomatic nocturnal enuresis, and determined predictive factors for treatment success.
MATERIALS AND METHODS: A total of 142 children with primary monosymptomatic nocturnal enuresis were randomized to receive treatment consisting of desmopressin or enuretic alarm for 6 months. Treatment compliance and response were reviewed monthly in each patient using a 30-day bed-wetting diary. Outcomes were assessed according to International Children's Continence Society criteria, and success rates at 6 and 12 months were compared for desmopressin and enuretic alarm. Additional intention to treat analyses were performed, considering cases with missing data as failures. Possible demographic factors predicting success were investigated by logistic regression analysis.
RESULTS: Overall 4 children (5.2%) in the desmopressin group and 20 (30.7%) in the enuretic alarm group withdrew after randomization. Based on patients who completed 6 months of treatment, success (more than 90% reduction in wet nights per month) was achieved in 76.8% and 61.8% of children in the desmopressin and enuretic alarm groups, respectively. At 12 months 77.8% of those receiving desmopressin and 75% of those treated with enuretic alarm had success. However, long-term success rate was significantly higher with desmopressin (68.8% vs 46.2%) if intention to treat population was considered. Multivariate analysis revealed treatment group, severity of enuresis and monthly income as independent predictors of cure at 6 months.
CONCLUSIONS: In compliant patients desmopressin lyophilisate and enuretic alarm provided equivalent success at the end of treatment and after extended followup. Alarm therapy had a high rate of early withdrawal from therapy and consequently lower rates of success on intention to treat analyses. Severe enuresis (more than 5 wet nights weekly) is an important predictive factor for cure after first-line treatment.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical alarms; comparative study; deamino arginine vasopressin; nocturnal enuresis

Mesh:

Substances:

Year:  2014        PMID: 25158273     DOI: 10.1016/j.juro.2014.08.088

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Alarm therapy and desmopressin in the treatment of patients with nocturnal enuresis.

Authors:  Basri Cakiroglu; Ersa Arda; Tuncay Tas; Aykut Bugra Senturk
Journal:  Afr J Paediatr Surg       Date:  2018 Jul-Dec

2.  Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial.

Authors:  Myungsun Shim; Woo Jin Bang; Cheol Young Oh; Min Jae Kang; Jin Seon Cho
Journal:  Investig Clin Urol       Date:  2021-03-16

3.  Alarm interventions for nocturnal enuresis in children.

Authors:  Patrina Hy Caldwell; Miriam Codarini; Fiona Stewart; Deirdre Hahn; Premala Sureshkumar
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

4.  Behavioral factors for predicting severity of enuresis and treatment responses in different compliance groups receiving behavioral therapy.

Authors:  Yanli Ma; Xiaomei Liu; Ying Shen
Journal:  Pak J Med Sci       Date:  2017 Jul-Aug       Impact factor: 1.088

5.  Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis.

Authors:  Carol Chiung-Hui Peng; Stephen Shei-Dei Yang; Paul F Austin; Shang-Jen Chang
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

6.  Association between enuresis and obesity in children with primary monosymptomatic nocturnal enuresis.

Authors:  Yanli Ma; Ying Shen; Xiaomei Liu
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

Review 7.  Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis.

Authors:  Konstantinos Kamperis; Charlotte Van Herzeele; Soren Rittig; Johan Vande Walle
Journal:  Pediatr Nephrol       Date:  2016-04-12       Impact factor: 3.714

8.  A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial.

Authors:  Parvin Mousavi Ghanavati; Dinyar Khazaeli; Mohammadreza Amjadzadeh
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.